Brand name: Jardiance
Public Citizen has been assessing the quality and efficacy of drugs and devices since its founding in 1971. We use the law, petitions, and letters to monitor the FDA and coax the agency into action. Our actions have contributed to many drugs being pulled off the market. Public Citizen has also been instrumental in getting “black box” and other warnings on drugs. Our advocacy work on this drug is available below.
If you are interesting in reading our evaluations of the safety and efficacy of medications as well as information on drug side effects and interactions, please visit WorstPills.org.
More information on empagliflozin (Jardiance)
- Petition to the FDA to Require a Black-Box Warning for Commonly Used Type 2 Diabetes Drugs Known as SGLT2 Inhibitors, June 24, 2020
- Testimony Before the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee Regarding Using Empagliflozin to Treat Patients with Type 1 Diabetes, November 13, 2019